OncoArendi licenses Cresset molecule design software to advance the development of new therapeutics

OncoArendi licenses Cresset molecule design software to advance the development of new therapeutics

Cambridge, UK – 21 July 2021 – Cresset, innovative provider of outstanding software for molecule discovery and design, is pleased to announce that OncoArendi Therapeutics SA (WSE: OAT), a biotechnology company which specializes in the discovery and development of new drugs, has licensed Flare™ for use in its internal development programs.

Cresset software uses its proprietary descriptors of shapes and electrostatics to help chemists understand the key interactions that underpin biological activity. The recent release of Flare V5 incorporates the best of Cresset’s ligand and structure-based technologies into a single platform. It features new and enhanced science, and an intuitive GUI to enable more effective and efficient molecule design.

“We are delighted that OncoArendi has chosen Flare to support their vital research” says Dr David Bardsley, Commercial Director, Cresset. “We’re confident that our innovative ligand and structure-based design methods will help provide fresh insights and advance their internal drug discovery programs.”

“The starting points of the two projects in which OncoArendi successfully selected candidates for clinical trials were molecules (lead structures), advanced in terms of their pharmacological properties. The purchase of Flare software will help us in the effective development of research programs in which such starting structures have yet to be found. The Cresset software will also allow us to better understand the observed relationships between the structure of the chemical compounds we test and their observed biological activity.” says Dr Jacek Olczak, Head of Medicinal Chemistry and Co-founder, OncoArendi.